{"name":"Arch Biopartners","slug":"arch","ticker":"ARCH.V","exchange":"TSXV","domain":"archbiopartners.com","description":"Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.","hq":"Toronto, Ontario, Canada","founded":0,"employees":"","ceo":"Richard Bhella","sector":"Anti-Infective / Organ Protection","stockPrice":0.43,"stockChange":0,"stockChangePercent":0,"marketCap":"$21M","metrics":{"revenue":115184.3423895,"revenueGrowth":0,"grossMargin":-284.9,"rdSpend":0,"netIncome":-1964312.7768615,"cash":3033.3720315,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Arch Biopartners Announces FDA Clearance for AB569","summary":"Arch Biopartners announced that the FDA has cleared AB569 for use as a topical antimicrobial treatment for wound care.","drugName":"AB569","sentiment":"positive"},{"date":"2022-11-29","type":"earnings","headline":"Arch Biopartners Reports Third Quarter 2022 Financial Results","summary":"Arch Biopartners reported its third quarter 2022 financial results, with a net loss of $1.1 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQZTB5N1F2dXgyXzZodUp5bzhIYTVZZUItdmtmRWpocGt3SGJaMF9YX1o1amhxRWIwSVQ0cEpPblR4VTFJS2FOTGtTcTdDamQ1Y2o3NWo4TmhYTnZvd2RzeHNlY3pEVDRPVF9sRUJJd2hBSF8tclBzMG9UOXJaN3VzUTI2UGI3ZXk0NlNvbDRNRXhKdGlpdGVFQWJ5eDF5QldmSGhHWE1oSktBLVU3SzBOUUw2ZUpydDZGcWQ3VHVfZE1nZXM4MllF?oc=5","date":"2026-03-30","type":"deal","source":"GlobeNewswire","summary":"Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewswire","headline":"Arch Biopartners Arranges Non-Brokered Private Placement","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"trial","source":"The Manila Times","summary":"Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide - The Manila Times","headline":"Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNUGVWQVNEMkYwOGVfX2dEOTdmOXJrSVF3ZXNING5NOWZENFlNVnZZbnNoam51TnlyMGlUSnFoNDlZN0VVaW9uTEpMUHZrdU1fc1ViT04zc2h4aU1WR2V3c2RXcWRlYjNCUDR2NEhIaFh3ZWdfYmJnUUpGR0lPRGhNdjRNVWxCNVl0V0haY0Nza21DT3NtN3dOMklnQnZCblFIWDlva05remM3dU0zWEQzajltbXlnLWtWUmJvdGFrV25JN09qV0hvWjVQcEI1RW4yZFBHSkxDXzhKU05kcGR0YzNwTjJ2QQ?oc=5","date":"2026-02-10","type":"patent","source":"Streetwise Reports","summary":"Technically Oversold with Support Solid Patents & A Heavyweight Board: Is This Stock Set to Soar? - Streetwise Reports","headline":"Technically Oversold with Support Solid Patents & A Heavyweight Board: Is This Stock Set to Soar?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOUlkzWnFSd1MtSFV3amNwdEF6d21fdkxpRXB0VklHLVMxaHZ5Rl9ic2NjWnF5X2tLTndDdEpRZGFHZW5UcWpJMEZiU1U1VnJFbFhzdTVHX2hIQW1rM0FBNXUwN3V2aDF6V2h4bjZBUXlDT1A1VXNucldINXYwc2w0OFlneVdjNUYtX0hYVEhYQzI?oc=5","date":"2026-01-16","type":"deal","source":"Yahoo Finance","summary":"Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board - Yahoo Finance","headline":"Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-17","type":"pipeline","source":"GlobeNewswire","summary":"Arch Strengthens its Position as a Leading Kidney - GlobeNewswire","headline":"Arch Strengthens its Position as a Leading Kidney","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Johnson & Johnson"],"therapeuticFocus":["Anti-infective","Organ protection"],"financials":{"source":"yahoo_finance","revenue":0,"revenuePeriod":"2025-09-30","revenueHistory":[{"period":"2025-09-30","value":0},{"period":"2024-09-30","value":0},{"period":"2023-09-30","value":0},{"period":"2022-09-30","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":-6935.295459,"rdSpendHistory":[{"period":"2025-09-30","value":-6935.295459},{"period":"2024-09-30","value":2656217.4321465},{"period":"2023-09-30","value":1413957.2250075},{"period":"2022-09-30","value":926913.386448}],"sgaSpend":835751.922393,"operatingIncome":-904748.5668885,"operatingIncomeHistory":[{"period":"2025-09-30","value":-904748.5668885},{"period":"2024-09-30","value":-2592338.1001125},{"period":"2023-09-30","value":-2183197.9297605},{"period":"2022-09-30","value":-786965.856816}],"netIncome":-1131407.691972,"netIncomeHistory":[{"period":"2025-09-30","value":-1131407.691972},{"period":"2024-09-30","value":-2856519.811344},{"period":"2023-09-30","value":-2424022.020564},{"period":"2022-09-30","value":-1025835.7069785}],"eps":-0.024,"epsHistory":[{"period":"2025-09-30","value":-0.024},{"period":"2024-09-30","value":-0.062},{"period":"2023-09-30","value":-0.053},{"period":"2022-09-30","value":-0.023}],"cash":1531.623351,"cashHistory":[{"period":"2025-09-30","value":1531.623351},{"period":"2024-09-30","value":2164.091985},{"period":"2023-09-30","value":605707.4870864999},{"period":"2022-09-30","value":368950.723374}],"totalAssets":76165.836765,"totalLiabilities":2904448.983933,"totalDebt":1818025.9878795,"equity":-2828283.1471679998,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":-1154244.3272925,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":677441.6715105,"ebit":-1074194.7833625,"ebitda":-1074194.7833625,"period":"2025-12-31","revenue":0,"epsBasic":-0.024,"netIncome":-1136243.01669,"rdExpense":344814.1755615,"epsDiluted":-0.024,"grossProfit":null,"operatingIncome":-1078433.343321},{"sga":218472.73671599998,"ebit":-151174.576536,"ebitda":-151174.576536,"period":"2025-09-30","revenue":0,"epsBasic":null,"netIncome":-196559.301579,"rdExpense":-206576.0600025,"epsDiluted":null,"grossProfit":null,"operatingIncome":-158055.2232075},{"sga":165339.542256,"ebit":-133678.22073,"ebitda":-133678.22073,"period":"2025-06-30","revenue":0,"epsBasic":-0.004,"netIncome":-176576.790267,"rdExpense":65773.09468349999,"epsDiluted":-0.004,"grossProfit":null,"operatingIncome":-157719.315327},{"sga":265703.862126,"ebit":-406245.970566,"ebitda":-406245.970566,"period":"2025-03-31","revenue":0,"epsBasic":-0.009,"netIncome":-454935.1256265,"rdExpense":76898.1305175,"epsDiluted":-0.009,"grossProfit":null,"operatingIncome":-379733.293473},{"sga":186237.9672465,"ebit":-252222.37057499998,"ebitda":-252222.37057499998,"period":"2024-12-31","revenue":0,"epsBasic":-0.006,"netIncome":-303337.93180049997,"rdExpense":56969.5393425,"epsDiluted":-0.006,"grossProfit":null,"operatingIncome":-209243.649483},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.43,"previousClose":0.43,"fiftyTwoWeekHigh":1.95,"fiftyTwoWeekLow":0.39,"fiftyTwoWeekRange":"0.39 - 1.95","fiftyDayAverage":0.55,"twoHundredDayAverage":1.08,"beta":2.05,"enterpriseValue":22887199.293297,"forwardPE":0,"priceToBook":-7.96,"priceToSales":184.79,"enterpriseToRevenue":198.7,"enterpriseToEbitda":0,"pegRatio":0,"ebitda":0,"ebitdaMargin":0,"freeCashflow":-554752.228971,"operatingCashflow":-1115539.141383,"totalDebt":1918713.099921,"debtToEquity":0,"currentRatio":0.01,"returnOnAssets":-524,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":968803200,"insiderHeldPercent":19.2,"institutionHeldPercent":0,"sharesOutstanding":67933289,"floatShares":52329115,"sharesShort":27106,"shortRatio":0.3,"shortPercentOfFloat":0,"epsTrailing":-0.04,"epsForward":0,"revenuePerShare":0,"bookValue":-0.05,"officers":[{"age":54,"name":"Mr. Richard Gabriel Muruve","title":"Co-Founder, CEO, President & Director"},{"age":null,"name":"Dr. Daniel Abraham Muruve M.D.","title":"Co-Founder, Chief Science Officer & Member of Scientific Advisory Board"},{"age":59,"name":"Mr. Andrew  Bishop CFA","title":"CFO & Director"},{"age":null,"name":"Dr. Justin  MacDonald Ph.D.","title":"Co-Founder & Principal Scientist"},{"age":null,"name":"Dr. Paul  Beck","title":"Co-Founder & Principal Scientist"},{"age":null,"name":"Mr. Aaron  Benson","title":"Director of Communications & Clinical Data Management"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.archbiopartners.com","phone":"647-428-7031"}}